Background Human papillomavirus (HPV) has proven to be the cause of several severe
clinical conditions on the cervix, vulva, vagina, anus, oropharynx and penis. Several studies …

Background We assessed the effectiveness of the quadrivalent human papillomavirus
vaccine (qHPV) vaccination program in Manitoba, Canada, in reducing incident anogenital …

Background: Little non-clinic-based data are available on incident genital warts rates and
related healthcare use. Goal: The goal of this study was to describe the incidence and …

In Québec province in Canada, a public school‐based and catch‐up HPV vaccination
programs with the quadrivalent vaccine have been introduced in September 2008 for girls …

BACKGROUND Typically occurring on the external genitalia, anogenital warts (AGWs) are
benign epithelial skin lesions caused by human papillomavirus infection. AGWs are usually …

Objectives To assess the prevalence and correlates of self-reported genital warts (GWs)
among women and men aged 18–45 years in the Baltic countries. Methods In 2011–2013 …

Objective To describe the burden and the predictors of genital warts (GWs) in Czech men
and women. Methods A population-based cross-sectional study was conducted of 32 974 …

BACKGROUND: The use of human papillomavirus (HPV) vaccines has been universally
approved for women from age 12 to 25 years, but those older than 16 years receive no …

Background The quadrivalent human papillomavirus (HPV) vaccine was introduced in the
Portuguese National Immunization Program in October 2008, targeting 13-year-old girls …

The prevalence of genital warts (GW) and self-reported human papillomavirus (HPV) as well
as disease-related psychosocial impact among male and female patients aged 18–60 years …